Foxo Technologies FOXO

FOXO Technologies Inc. is a healthcare services and technology company delivering integrated healthcare solutions across multiple operational domains. The company focuses on improving community health outcomes through behavioral health services, critical access hospital operations, life science support services, and epigenetic diagnostics development. Its diversified operations span patient care, biological specimen sourcing, and advanced biomarker research targeting applications in healthcare and insurance underwriting.

FOXO Technologies Inc. generates revenue through four primary divisions aligned with its reportable segments. The Healthcare segment earns income from inpatient and outpatient behavioral health treatment services, critical access hospital operations including emergency care and ancillary services such as laboratory and pharmacy. The Life Science Services segment derives revenue from sourcing, preserving, and distributing human biological specimens—including blood, serum, urine, tissues, and living cells—to support pharmaceutical, biotechnology, and clinical research activities. The Labs segment is engaged in commercializing proprietary epigenetic biomarker technology for risk assessment in the life insurance industry, utilizing saliva-based testing to inform underwriting models, though revenue generation remains limited due to ongoing development and capital constraints.

The company operates through the following segments: Healthcare, Life Science Services, and Labs.

• Healthcare: This segment encompasses behavioral health treatment and critical access hospital services delivered through acquired subsidiaries. Myrtle Recovery Centers, Inc. provides substance use disorder treatment via inpatient, residential, and outpatient programs, including detoxification and rehabilitation for up to 30 patients, along with office-based opiate treatment services. Rennova Community Health, Inc. operates Scott County Community Health, Inc., doing business as Big South Fork Medical Center, a 25-bed Critical Access Hospital in Oneida, Tennessee offering 24/7 emergency care, laboratory, radiology, respiratory, and pharmacy services, with recent expansions in tele-specialty and cardiac diagnostics.
• Life Science Services: This segment focuses on the procurement and distribution of high-quality biological materials for research purposes. Vector BioSource Inc. serves the biotechnology, clinical research, and pharmaceutical industries by sourcing human biospecimens such as blood, serum, urine, tissues, and living cells from global partners. The company maintains specialized logistics and preservation capabilities to ensure sample integrity during transportation and storage, supporting clinical trials and diagnostic development efforts for third-party researchers and institutions.
• Labs: This segment is dedicated to advancing epigenetic biomarker technology for health risk assessment. FOXO Labs develops saliva-based epigenetic tests that measure biological aging and wellness indicators for potential use in life insurance underwriting. The company has secured USPTO Notices of Allowance for two patent applications involving machine learning models trained on DNA epigenetic data to classify risk and determine biochemical states, aiming to enable non-invasive health analytics through proprietary biomarker platforms.

FOXO Technologies Inc. occupies a niche position at the intersection of rural healthcare delivery, life science supply chain services, and precision biomarker innovation. While facing competition from larger healthcare systems in behavioral health and hospital operations, and established players in biospecimen distribution like Thermo Fisher Scientific and Merck KGaA, the company differentiates itself through vertical integration of patient care, specimen sourcing, and diagnostic innovation. Its focus on underserved rural markets and emerging epigenetic applications provides a strategic edge in specialized service areas where large entrants may have limited presence.

The company serves a diverse customer base including individuals seeking behavioral health treatment for substance use disorders, patients utilizing emergency and inpatient services at its Critical Access Hospital in Oneida, Tennessee, pharmaceutical and biotechnology firms requiring human biospecimens for research and development, and clinical laboratories engaged in translational science. Additionally, the Labs segment targets life insurance providers and underwriting entities as future clients for its epigenetic risk assessment tools, though commercial adoption remains pending due to developmental stage.